Recently, immune checkpoint inhibitors (ICIs) have brought a major breakthrough, especially those targeting the programmed death receptor (PD - 1) and programmed death ligand 1 (PD-L1), which have become the standard treatment for driver-negative advanced NSCLC. Here, RPL17 is linked to non-small cell lung carcinoma.